PMID- 26383631
OWN - NLM
STAT- MEDLINE
DCOM- 20160125
LR  - 20151010
IS  - 1879-3169 (Electronic)
IS  - 0378-4274 (Linking)
VI  - 239
IP  - 2
DP  - 2015 Dec 3
TI  - Human placental cell and tissue uptake of doxorubicin and its liposomal 
      formulations.
PG  - 108-14
LID - S0378-4274(15)30051-5 [pii]
LID - 10.1016/j.toxlet.2015.09.011 [doi]
AB  - The anticancer drug doxorubicin and its liposomal formulations are in clinical 
      use, doxorubicin also during pregnancy. However, little is known about how 
      doxorubicin and its liposomal formulations are taken up by placental cells and 
      whether they can cross human placenta. We therefore investigated quantitative 
      cellular uptake and toxicity of doxorubicin and its two liposomal formulations, 
      pH-sensitive liposomal doxorubicin (L-DOX) and commercially available pegylated 
      liposomal doxorubicin (PL-DOX), in human placental choriocarcinoma (BeWo) cells. 
      PL-DOX showed significantly lower cellular uptake and toxicity compared with 
      doxorubicin and L-DOX. In preliminary studies with human placental perfusion, 
      PL-DOX did not cross the placenta at all in 4h, whereas doxorubicin and L-DOX 
      crossed the placenta at low levels (max 12% of the dose). Furthermore, PL-DOX did 
      not accumulate in placental tissue while doxorubicin did (up to 70% of the dose). 
      Surface pegylation probably explains the low placental cell and tissue uptake of 
      PL-DOX. Formulation of doxorubicin thus seems to enable a decrease of fetal 
      exposure.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Soininen, Suvi K
AU  - Soininen SK
AD  - School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 
      Kuopio Campus, P.O. Box 1627, FI-70211 Kuopio, Finland. Electronic address: 
      karoliina.soininen@uef.fi.
FAU - Repo, Jenni K
AU  - Repo JK
AD  - School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 
      Kuopio Campus, P.O. Box 1627, FI-70211 Kuopio, Finland.
FAU - Karttunen, Vesa
AU  - Karttunen V
AD  - School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 
      Kuopio Campus, P.O. Box 1627, FI-70211 Kuopio, Finland.
FAU - Auriola, Seppo
AU  - Auriola S
AD  - School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 
      Kuopio Campus, P.O. Box 1627, FI-70211 Kuopio, Finland.
FAU - Vahakangas, Kirsi H
AU  - Vahakangas KH
AD  - School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 
      Kuopio Campus, P.O. Box 1627, FI-70211 Kuopio, Finland.
FAU - Ruponen, Marika
AU  - Ruponen M
AD  - School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 
      Kuopio Campus, P.O. Box 1627, FI-70211 Kuopio, Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150914
PL  - Netherlands
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Liposomes)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antibiotics, Antineoplastic/administration & dosage/*pharmacokinetics
MH  - Cell Line, Tumor
MH  - Cell Survival
MH  - Doxorubicin/administration & dosage/analogs & 
      derivatives/chemistry/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - Liposomes
MH  - Placenta/*cytology/*metabolism
MH  - Pregnancy
OTO - NOTNLM
OT  - BeWo cells
OT  - Doxil
OT  - Doxorubicin
OT  - Human placental perfusion
OT  - Liposome
OT  - Pregnancy
EDAT- 2015/09/19 06:00
MHDA- 2016/01/26 06:00
CRDT- 2015/09/19 06:00
PHST- 2015/07/09 00:00 [received]
PHST- 2015/09/08 00:00 [revised]
PHST- 2015/09/11 00:00 [accepted]
PHST- 2015/09/19 06:00 [entrez]
PHST- 2015/09/19 06:00 [pubmed]
PHST- 2016/01/26 06:00 [medline]
AID - S0378-4274(15)30051-5 [pii]
AID - 10.1016/j.toxlet.2015.09.011 [doi]
PST - ppublish
SO  - Toxicol Lett. 2015 Dec 3;239(2):108-14. doi: 10.1016/j.toxlet.2015.09.011. Epub 
      2015 Sep 14.